Köttgen Anna, Hsu Charles C, Coresh Josef, Shuldiner Alan R, Berthier-Schaad Yvette, Gambhir Tejal Rami, Smith Michael W, Boerwinkle Eric, Kao W H Linda
Johns Hopkins University, Baltimore, MD, USA.
Am J Kidney Dis. 2008 Nov;52(5):868-75. doi: 10.1053/j.ajkd.2008.02.306. Epub 2008 May 21.
Rare mutations in nephrosis 2 (NPHS2), encoding podocin, are found in patients with familial and sporadic steroid-resistant nephrotic syndrome and focal segmental glomerular sclerosis. The objective of this study is to assess the contribution of the commonly reported functional podocin polymorphism R229Q to kidney disease in the population at large and replicate a prior study of an association of R229Q and albuminuria in the general population.
Large sample of the Atherosclerosis Risk in Communities (ARIC) Study, a population-based prospective study.
SETTING & PARTICIPANTS: 4,424 white and 3,746 black middle-aged adults.
Genotype at the R229Q polymorphism in podocin.
Urinary albumin-creatinine ratio (ACR) and decreased estimated glomerular filtration rate (eGFR) as measures of kidney damage/dysfunction.
Crude and multivariable adjusted linear and logistic regression models.
R229Q allele frequencies were 3.7% in 4,424 white and 0.6% in 3,746 black individuals. No significant association of R229Q with increased ACR or decreased eGFR was observed (adjusted odds ratio of ACR > or = 30 mg/g in RQ/QQ versus RR carriers, 1.18; 95% confidence interval, 0.76 to 1.84; adjusted odds ratio of eGFR < 60 mL/min/1.73 m(2) in RQ/QQ versus RR carriers, 1.18; 95% confidence interval, 0.76 to 1.83). As expected, the established kidney disease risk factors hypertension and diabetes mellitus were associated strongly with measures of kidney damage/dysfunction, but the R229Q polymorphism was not associated with an additional increase in kidney disease measures.
Single measurement of ACR, subsample of all ARIC participants.
No significant association of the relatively rare R229Q variant and ACR or eGFR was found in either white or black individuals. The phenotypic effect of a variant as R229Q would have to be of great magnitude to meaningfully contribute to the risk of kidney disease on a population level. The importance of such variants in the general population, as well as replication studies, can be evaluated best in large community-based studies that allow for accounting of established disease risk factors.
编码足突蛋白的肾病2(NPHS2)基因中的罕见突变,在家族性和散发性类固醇抵抗性肾病综合征以及局灶节段性肾小球硬化症患者中被发现。本研究的目的是评估普遍报道的功能性足突蛋白多态性R229Q对普通人群肾脏疾病的影响,并重复先前关于普通人群中R229Q与蛋白尿关联的研究。
社区动脉粥样硬化风险(ARIC)研究的大样本,一项基于人群的前瞻性研究。
4424名白人及3746名黑人中年成年人。
足突蛋白R229Q多态性的基因型。
以尿白蛋白肌酐比值(ACR)升高和估计肾小球滤过率(eGFR)降低作为肾脏损伤/功能障碍的指标。
粗线性和多变量校正线性及逻辑回归模型。
在4424名白人中,R229Q等位基因频率为3.7%,在3746名黑人中为0.6%。未观察到R229Q与ACR升高或eGFR降低有显著关联(RQ/QQ携带者与RR携带者相比,ACR≥30mg/g的校正比值比为1.18;95%置信区间为0.76至1.84;RQ/QQ携带者与RR携带者相比,eGFR<60mL/min/1.73m²的校正比值比为1.18;95%置信区间为0.76至1.83)。正如预期的那样,已确定的肾脏疾病危险因素高血压和糖尿病与肾脏损伤/功能障碍指标密切相关,但R229Q多态性与肾脏疾病指标的额外增加无关。
ACR单次测量,为所有ARIC参与者的子样本。
在白人或黑人个体中,均未发现相对罕见的R229Q变异与ACR或eGFR有显著关联。像R229Q这样的变异的表型效应必须非常大,才能在人群水平上对肾脏疾病风险有显著影响。在考虑已确定的疾病危险因素的大型社区研究中,能最好地评估此类变异在普通人群中的重要性以及重复研究。